Information  X 
Enter a valid email address

IDOX PLC (IDOX)

  Print          Annual reports

Friday 23 April, 2021

IDOX PLC

Exercise of Share Options & Total Voting Rights

RNS Number : 4941W
IDOX PLC
23 April 2021
 

Idox plc

( ' Idox '   or the  ' Group '   or the  ' Company ' )

Exercise of Share Options &

Total Voting Rights

 

Idox plc (AIM: IDOX), a leading supplier of specialist information management solutions and services, announces that it has issued 468,556 new Ordinary shares of 1 pence each in the Company ("Ordinary Shares") pursuant to an exercise of options by three employees under its 2019 and 2020 Idox plc Long Term Incentive Plans.

Applications have been made for the 468,556 new Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will occur at 8.00 a.m. on or around 26 April 2021.

The total number of Ordinary Shares in issue following Admission will be 446,630,989 . The Company holds 1,426,219 Ordinary Shares in treasury. Therefore the total number of Ordinary Shares with voting rights in the Company will be 445,204,770 .

The above figure of 445,204,770 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

-Ends-

Enquiries:

Idox plc

+44 (0) 870 333 7101

Chris Stone, Non-Executive Chairman

 

David Meaden, Chief Executive

 

Rob Grubb, Chief Financial Officer

 

 

 

Peel Hunt LLP (NOMAD and Broker)

+44 (0) 20 7418 8900

Edward Knight

 

Paul Gillam

 

Nick Prowting

 

 

 

MHP Communications

+ 44 (0) 203 128 8100

Reg Hoare 

 [email protected]

James Bavister

 

Amy O'Sullivan

 

 

 

 

 

 

 

 

 

     

About Idox plc

For more information see  www.idoxplc.com   @Idoxgroup  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRZXLFLFZLEBBV

a d v e r t i s e m e n t